think u were spot on with the 8c CR skara. this is now pre-consolidation 0.4c. Crazy times in anyones language. And all rests on the heads of management. The worst performance by any management in my portolio, and i've got a bunch of penny stocks. I'll be contacting the company with my thoughts on their performance (a consolidation and 6mth pre-notice CR, when the SP was finally gaining some traction/momentum) and a please explain.
This hasn't changed the technology, although their complete silence on Co-X-gene is concerning. Transgene to announce new pre-clinical data at conference April 20th and working toward PhaseIII clinicals. http://www.businesswire.com/news/ho...l-Data-TG4010-Combination-Immune#.VRTp9_mUeSo http://www.businesswire.com/news/ho...ncial-Results-Outlines-Promising#.VRTqE_mUeSo
I know that license prob doesn't hold much $$ for PTX, but interest in the technology for other cancers would surely spike.
Any, bottom draw as you said skara. Note to self: never invest with the heart, only leads to heartache!
GLTA SHs.
PTX Price at posting:
8.2¢ Sentiment: Hold Disclosure: Held
